Bio-Rad Labs (NYSE: BIO) reported Q1 EPS of $2.29, $0.14 better than the analyst estimate of $2.15. Revenue for the quarter came in at $610.8 million versus the consensus estimate of $619.09 million.

GUIDANCE

Full-Year 2024 Financial Outlook

Bio-Rad is maintaining its financial outlook for the full year 2024. The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 1.0 to 2.5 percent and an estimated non-GAAP operating margin of approximately 13.5 to 14.0 percent.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.